Research & Development



  如果昌邑王子子孫孫無窮匱也,他們的子子孫孫也將無窮匱也。   不論是劉徹,還是阿嬌都沒有把這些人從樹上放下來。超碰人人最新上线视频   盡管如此,劉徹依舊是寒門子弟們心中最偉大的君王,不論如何,這位君王喜歡不拘一格的使用人才。超碰免费   董仲舒嘆息一聲道︰“三請,陛下必然會同意,就不勞君侯大駕了。”   霍光笑道︰“我問過了那些人了,他們國王住的地方也不過如此,唯一的缺憾就是沒有時間在石頭上雕刻花紋。”超碰免费视频caoponAV   “她想多要幾個孩子,我認為已經夠了!”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo